Thyroid Cancer

Researchers found several risk factors for regional nodal recurrence in patients with papillary thyroid cancer, all of which can be easily evaluated in the clinical setting.

Vitamin D deficiency may be a negative prognostic indicator for papillary thyroid cancer, according to the results of a recent retrospective study.

A recent study in Surgery found that thyroid cancer survivors reported increased complications related to surgery and radioactive iodine ablation.

A recent study evaluated the impact of recommendations encouraging less aggressive lobectomy for patients with small papillary thyroid cancers.

Researchers evaluated the impact of dose interruption on survival for lenvatinib vs placebo in patients with progressive differentiated thyroid cancer.

A meta-analysis looked at the controversial link between decreased serum 25-hydroxyvitamin D levels and incidence of thyroid cancer.

According to the American Thyroid Association guidelines, noninvasive follicular thyroid neoplasm with papillary-like features is benign.

Researchers evaluated the incidence of physical, psychological, and lifestyle effects among patients with differentiated thyroid cancer.

A 45-year-old man presents with neck pain and a mass in the thyroid gland. What is your diagnosis?

Researchers conducted the first population-based study of an unselected MTC cohort compared with the general population.

Clinicians may be able to utilize this information as an effective preoperative tool to stratify risk and determine an initial surgical approach for patients with PTC.

The thyroid screening program put in place after the 2011 Fukushima Daiichi nuclear power station accident resulted in the diagnosis of a number of pediatric thyroid cancers.

The performance of three international guidelines in detecting thryoid cancer was compared based on their sensitivity and fine-needle aspiration rates.

The authors looked at whether rates of malignancy and false-negative fine-needle aspiration results are heightened in large thyroid nodules.

A study in Thyroid evaluated the safety and efficacy of concurrent intensity-modulated radiation therapy and doxorubicin in thyroid cancer.

Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.

A new study in Cancer Management and Research found a correlation between the age of patients with papillary thyroid cancer and lymph node positivity.

LOXO-292, which selectively targets RET and has demonstrated preclinical activity against activating RET fusions/mutations, holds promise.

The eighth edition outperforms the seventh edition in predicting survival differences in patients with papillary thyroid cancer and follicular thyroid cancer.

The study confirmed a significant effect of male sex on PTC-specific patient survival in individuals with the most frequent oncogenic mutation.

A study shows that receipt of radioactive iodine after reoperation may not be associated with improved outcomes.

The steep increase in thyroid cancer diagnosis has not been mirrored by increasing mortality rates and is likely due to widespread overdiagnosis of small neoplasms.

Korean investigators concluded that, in terms of recurrence risk, a qualified high-volume surgeon may be optimal for performing the initial surgery in this setting.

Brazilian researchers say their study results “suggest the overall DNA methylation profile may be influenced by the histological subtype of thyroid cancer.”

In an exclusive interview, thyroid cancer expert and surgeon Dr. Louise Davies discusses overdiagnosis and overtreatment of subclinical thyroid cancers.

Next-generation sequencing may prove to be a useful tool in the identification of co-mutations associated with resistance, an MD Anderson study suggests.

In the Utah Cancer Survivors Study, male thyroid cancer survivors had an almost 50% higher risk of developing cardiovascular disease than females.

The study is potentially a “leap forward” in cancer genomics, particularly for subsets of patients with metastatic and anaplastic thyroid cancer.

The approval should have a profound impact on patients with the rare tumor, according to experts.

Certain genetic alterations associated with anaplastic transformation in thyroid cancer made patients sensitive to the multikinase inhibitor lenvatinib.